Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Zelgen Biopharmaceuticals Co Days Payable Chart
SHSE:688266 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Suzhou Zelgen Biopharmaceuticals Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzhou Zelgen Biopharmaceuticals Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Suzhou Zelgen Biopharmaceuticals Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Suzhou Zelgen Biopharmaceuticals Co's Days Payable falls into.
Suzhou Zelgen Biopharmaceuticals Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a Days Payable of 859.38 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. This is 76% below median its historical median of 3,607.32. Over the past decade, Suzhou Zelgen Biopharmaceuticals Co's Days Payable has ranged from 968.13 to 775,559.82. According to the industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #100 out of 702 companies in the Biotechnology industry, placing it in the top 14.2%.
Is Suzhou Zelgen Biopharmaceuticals Co's Days Payable too high?
Suzhou Zelgen Biopharmaceuticals Co's current Days Payable of 859.38 is 76% below median its 10-year median of 3,607.32. Over the past 10 years, this metric has ranged from a low of 968.13 to a high of 775,559.82. The Biotechnology industry median Days Payable is 113.10. Suzhou Zelgen Biopharmaceuticals Co's value of 859.38 is 659.8% above this industry median. Based on the distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #100 out of 702 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Suzhou Zelgen Biopharmaceuticals Co ranks #100 out of 702 companies for Days Payable. This places Suzhou Zelgen Biopharmaceuticals Co in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 113.10. Suzhou Zelgen Biopharmaceuticals Co's value of 859.38 is 659.8% above this benchmark. Historically, Suzhou Zelgen Biopharmaceuticals Co's own Days Payable has ranged from 968.13 to 775,559.82 over the past decade. While the company's 10-year median is 3,607.32 vs. the industry median of 113.10, Suzhou Zelgen Biopharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzhou Zelgen Biopharmaceuticals Co's current Days Payable of 859.38 is 659.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzhou Zelgen Biopharmaceuticals Co's current Days Payable is 859.38, which is 76% below median its own 10-year median of 3,607.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥216.30, compared to a current price of ¥140.00 — trading 35.3% below its estimated fair value. The current Days Payable is 859.38, which is 76% below median its 10-year median of 3,607.32 and 659.8% above the Biotechnology industry median of 113.10. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current Days Payable is 859.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥140.00 is trading 35.3% below its estimated GF Value™ of ¥216.30.
GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.
Key valuation signals for SHSE:688266:
Days Payable: 859.38 (76% below median its 10-year median of 3,607.32)
GF Value™: ¥216.30 vs. price of ¥140.00 (35.3% below fair value)
Industry Position: 659.8% above the Biotechnology median (#100 of 702)
No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzhou Zelgen Biopharmaceuticals Co Business Description
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
67GF Score
Get the complete analysis for SHSE:688266
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688266 has been successfully added to your 
